Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 25/05/18 at 11:08am

It's a special Firday here in Europe, as today marks the advent of the General Data Protection Regulation (GDPR), an important step in recognising the rights of citizens to their own data. It also marks the print date of our upcoming June issue, whcih will include a special feature on the topic of the moment: data management.

As always, it's been a packed week in the industry. Of note is the shocking news that, given current health trends, the world is heading towards one in four poeple being obese by 2045, while researchers also claim to have discovered the possible cause of acute lymphoblastic leukaemia, the msot ocmmon form of childhood cancer.

Check out the week's ten most popular articles on Pharmafile.com now!

10. Vifor Fresenius snap up rights to Cara’s itch therapy

The joint partnership between Vifor Pharma and Fresenius Medical Care, Vifor Fresenius, has put down $50 in upfront cash and an equity investment of $20 million to gain the Ex-US, Japan and South Korea rights to Cara Therapeutics’ Korsuva.

9. Gilead expands operations in Cork, Ireland

Gilead has unveiled the expansion of its Cork manufacturing site, involved in the creation of its treatments for HIV and hepatitis.

8. UK MPs call for Brexit priority over pharma industry

A new report published by the Business, Energy and Industrial Strategy Committee has called for the UK government to ensure that the pharmaceutical industry is aligned as closely as possible to European regulation post-Brexit.

7. World heading towards 25% of total population being obese

The latest global research paints a bleak picture of future global public health, predicting that almost a quarter of the entire global population will be obese by 2045, based on current trends.

6. Novartis' Sandoz scores EU approval for Remicade biosimilar

The European Commission has given its approval to Sandoz, Novartis’ generics and biosimilars unit, for its biosimilar version of Janssen’s Remicade (infliximab) and other products, known as Zessly.

5. The cause of the most common form of childhood cancer found

Professor Mel Greaves, of The Institute of Cancer Research, has spent 30 years uncovering what is behind the mysterious rise in rates of acute lymphoblastic leukaemia in children.

4. Roche’s Hemlibra stakes claim to be haemophilia market leader

Hemlibra was widely expected to become the dominant therapeutic for treating haemophilia patients and its latest clinical trial results only cements its prospects in the field.

3. Clinical trials, Brexit and the question of ‘full alignment’

Gene Matthews, Partner at Leigh Day, reviews the tough decisions the UK has to make regarding its position in the EU regulatory framework post-Brexit.

2. EMA review confirms risks of Abbvie and Biogen's Zinbryta outweigh benefits

The EMA has judged that the benefits offered by Zinbryta do not outweigh its risks, following a review carried out by the agency’s Pharmacovigilance Risk Assessment Committee (PRAC) at the request of the European Commission.

1. Astellas begins major restructure, as 600 jobs slashed

Astellas, under the direction of new CEO, Kenji Yasukawa, has unveiled a major new restructure, ahead of a difficult looking year financially in 2019.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches